Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

Pediatric eosinophilic esophagitis (EoE) is a chronic immune-mediated inflammatory disorder of the esophagus. A 2024 pediatric cohort of 256 children reported a mean diagnostic age of 9 years, 72% male representation, and 60% mucosal remission. A US analysis identified 20,435 EoE cases in 2022, with an overall prevalence of 163.08 per 100,000. According to pediatric eosinophilic esophagitis (eoe) epidemiology forecast by Expert Market Research (EMR), eosinophilic esophagitis has an overall incidence of approximately 33.9 cases per 100,000 patient-years and prevalence of approximately 147.4 cases per 100,000 individuals, although these figures encompass the broader EoE population rather than children specifically.

2025

Base Year

2019-2025

Historical Period

2026-2035

Forecast Period

Pediatric Eosinophilic Esophagitis (EoE) – Number of Cases by Year

Read more about this report - Request a Free Sample

Pediatric Eosinophilic Esophagitis (EoE) Epidemiology Forecast Report Coverage

Expert Market Research's “Pediatric Eosinophilic Esophagitis (EoE) Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of Pediatric Eosinophilic Esophagitis (EoE). It projects the future incidence and prevalence rates of Pediatric Eosinophilic Esophagitis (EoE) cases across various populations. The study covers age, gender, and type as major determinants of the Pediatric Eosinophilic Esophagitis (EoE) population. The report highlights patterns in the prevalence of Pediatric Eosinophilic Esophagitis (EoE) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of Pediatric Eosinophilic Esophagitis (EoE) in the 8 major markets.

Regions Covered

  • United States
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

Pediatric Eosinophilic Esophagitis (EoE) Understanding: Disease Overview

Pediatric eosinophilic esophagitis (EoE) is a chronic, immune-mediated inflammatory disorder of the esophagus characterized by esophageal dysfunction and eosinophil-predominant inflammation. Pediatric EoE develops through predominantly type 2 immune mechanisms involving epithelial alarmins, cytokines such as IL-4, IL-5 and IL-13, eosinophilic recruitment and esophageal tissue remodeling. Clinical presentation varies considerably with age: younger children commonly develop feeding difficulties, vomiting and poor weight gain, whereas older children and adolescents more frequently present with dysphagia and food impaction.

Key Report Insights

Parameter

Insight

Largest Patient Pool

United States

Fastest Growing Region

Japan

High-Risk Population

Boys and children with atopic disease represent important high-risk groups. A 2024 pediatric cohort found 72% of affected children were male, while a separate pediatric study reported 70% male representation and 67% White identification. Atopy, asthma, food allergy and other allergic conditions are frequently associated with pediatric EoE.

Key Diagnostic Method

Upper gastrointestinal endoscopy with multiple esophageal biopsies remains the key diagnostic procedure. Diagnosis requires compatible symptoms together with esophageal histology demonstrating at least 15 eosinophils per high-power field after appropriate clinical assessment. The 2024 ESPGHAN guideline emphasizes systematic biopsy sampling because endoscopic appearance alone can be normal despite active histological disease.

Major Risk Factor

Atopic predisposition is a major risk context, with food allergy, asthma, allergic rhinitis and atopic dermatitis frequently accompanying EoE. Genetic susceptibility and environmental exposures also contribute. In the 2024 Asian meta-analysis, a history of atopy was reported in 57.2% of patients with EoE, although estimates varied between individual studies.

Major gap in the market

Major unmet needs include delayed diagnosis, repeated endoscopies for histological monitoring, restrictive elimination diets, limited pediatric specialist availability and incomplete long-term disease control. Although dupilumab expanded treatment options in 2024 for children aged 1 year and older weighing at least 15 kg, access, long-term treatment strategy and disease monitoring remain important gaps.

Pediatric Eosinophilic Esophagitis (EoE) Epidemiology Perspective

The Pediatric Eosinophilic Esophagitis (EoE) epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the Pediatric Eosinophilic Esophagitis (EoE) epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Pediatric Eosinophilic Esophagitis (EoE) and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

The global pooled prevalence of EoE was 40.04 cases per 100,000 inhabitants in a systematic review encompassing 40 studies, more than 288 million participants and 147,668 EoE cases. Prevalence increased to 74.42 per 100,000 during 2017-2022. Pediatric-specific estimates vary substantially according to geography and case ascertainment.

Gender-Specific Cases of the Disease

Pediatric EoE demonstrates a consistent male predominance. A 2024 cohort of 256 children reported 184 males, corresponding to 72% of the study population. Another 2024 pediatric phenotype study reported 70% male representation. This approximately 2-3:1 male predominance is repeatedly observed in pediatric clinical cohorts, although its biological basis remains incompletely understood.

Age-Specific Cases of the Disease

Pediatric EoE can occur throughout childhood, but symptom phenotype changes with age. A 2024 cohort reported a mean diagnostic age of 9 years. Children younger than 2 years most commonly presented with vomiting, those aged 2-<6 years more frequently showed poor weight gain, while children aged 6-18 years more often presented with food impaction and abdominal pain.

Ethnicity-Wise Cases of the Disease

Contemporary ethnicity-specific prevalence data remain limited. A 2024 pediatric study reported that 67% of its 91 participants identified as White, but this represents the composition of a single multidisciplinary EoE clinic rather than population prevalence. Global meta-analysis indicates substantially higher EoE prevalence in high-income countries and North America, suggesting important geographic and environmental influences.

Mortality and Survival Analysis of the Disease

Pediatric EoE is generally associated with chronic morbidity rather than disease-specific mortality. Persistent inflammation can produce esophageal remodeling, strictures, dysphagia, and food impaction. In a 2024 pediatric cohort investigating age-specific outcomes, 99 of 164 children with available follow-up endoscopies, or 60%, achieved mucosal remission. Long-term disease control is therefore principally assessed through symptom, histological, and structural outcomes.

Type-Specific Disease Burden and Epidemiology Analysis

Disease Type

Prevalence

Inflammatory Phenotype

The inflammatory phenotype represents pediatric EoE dominated by active mucosal eosinophilic inflammation without established fibrostenotic disease. In a multicenter study, 84% of pediatric patients had an inflammatory phenotype, compared with 16% with fibrostenotic disease. Younger children more commonly presented with vomiting, abdominal pain and poor weight gain.

Fibrostenotic Phenotype

The fibrostenotic phenotype develops with chronic eosinophilic inflammation, fibrosis, rings and strictures. In the same pediatric study, 16% of children had fibrostenotic disease. Fibrostenotic disease was associated with greater need for dilation, while dysphagia and food impaction were more common with structural disease.

Mixed Inflammatory-Fibrostenotic Phenotype

The mixed phenotype combines active inflammation with structural remodeling, including dysphagia, food impaction and esophageal narrowing. Although pediatric-specific prevalence estimates for this phenotype remain limited, broader EoE data show that mixed disease represents a substantial proportion of patients with established fibrostenotic features.

Feeding-Dysfunction Predominant Phenotype

A 2025 systematic review of 10 studies found feeding difficulties in 13%–75.3% of children with EoE, although substantial variation existed between studies. A 2024 cohort of 256 children also found that younger patients more frequently presented with feeding difficulty and poor weight gain.

Pediatric Eosinophilic Esophagitis (EoE) – Number of Cases by Country

Read more about this report - Request a Free Sample

Country-wise Pediatric Eosinophilic Esophagitis (EoE) Epidemiology

The Pediatric Eosinophilic Esophagitis (EoE) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Country

Key Insights

United States

A 2024 analysis of two large US administrative databases identified 20,435 EoE cases in 2022 and estimated overall prevalence at 163.08 per 100,000. Prevalence was 204.45 per 100,000 among males and 122.06 per 100,000 among females. These estimates encompass all ages rather than pediatric EoE specifically but demonstrate the substantial recognized US disease burden.

Germany

Contemporary German pediatric data remain limited, but a 2026 prospective pediatric study specifically addressed this evidence gap and followed 50 children with EoE. The study reflects increasing recognition of pediatric EoE in Germany and emphasizes treatment success, atopic comorbidities and longitudinal disease monitoring. A robust nationwide pediatric prevalence estimate for Germany is not currently sufficiently established.

France

France contributes to European EoE surveillance and pediatric gastroenterology research, but a contemporary nationwide pediatric prevalence estimate is not sufficiently standardized for reliable presentation as a 2023-2026 national figure. European meta-analysis demonstrates increasing EoE incidence across countries and identifies substantial geographical variation, emphasizing the influence of diagnostic intensity and differences in endoscopic ascertainment.

Italy

Italy has developed dedicated pediatric EoE clinical guidance. The 2025 Italian guideline emphasizes multidisciplinary management involving pediatric gastroenterologists, allergists and dietitians, with endoscopy central to diagnosis and monitoring. Contemporary national prevalence remains incompletely characterized, although Italian pediatric research continues to demonstrate increasing recognition of eosinophilic gastrointestinal diseases and the need for standardized pediatric EoE pathways.

Spain

Spain represents one of the highest-burden European settings for EoE. A population-based study covering two Spanish regions reported pediatric EoE prevalence of 143.6 per 100,000 in 2024 and an average pediatric incidence of 15.74 per 100,000 person-years across 2006-2024, rising to 23.95 per 100,000 during the most recent decade. Pediatric prevalence had approximately doubled from earlier estimates.

United Kingdom

The UK contributes substantially to European EoE research, with contemporary European meta-analysis demonstrating increasing incidence over time and higher rates in regional studies than nationwide datasets. However, a single current nationwide pediatric prevalence estimate is not sufficiently standardized for direct reporting. Pediatric gastroenterology services increasingly emphasize biopsy-based diagnosis and long-term monitoring because EoE is a chronic disease.

Japan

A 2024 population-based Japanese study identified 1,010 EoE cases among 15.2 million insured individuals. Overall EoE incidence reached 2.82 per 100,000 person-years and prevalence 10.68 per 100,000 in 2022, nearly threefold and eightfold higher, respectively, than in 2017. These are all-age estimates, but they demonstrate rapidly increasing recognition of EoE in Japan.

India

A prospective Indian pediatric study involving 200 children undergoing elective upper gastrointestinal endoscopy identified EoE in 7 patients, corresponding to a hospital-based prevalence of 3.5%. Among 20 children evaluated for dysphagia, 4 had EoE, while 2 of 3 children presenting with food-bolus impaction and dysphagia had EoE. These findings support substantial under-recognition and the need for larger multicenter studies.

Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape

The principal epidemiological gap in pediatric EoE is the combination of increasing disease recognition with substantial diagnostic heterogeneity and limited population-based pediatric surveillance. Global meta-analysis found 40.04 cases per 100,000 overall, increasing to 74.42 per 100,000 during 2017-2022, while the European systematic review demonstrated significantly higher incidence in regional studies than nationwide studies. The Spanish 2024 population-based study provides particularly strong evidence of continued growth, reporting pediatric prevalence of 143.6 per 100,000 and an incidence of 23.95 per 100,000 during the most recent decade. In India, the 3.5% prevalence among children undergoing elective endoscopy illustrates the difference between general-population prevalence and prevalence in clinically selected pediatric populations.

Pediatric Eosinophilic Esophagitis (EoE): Treatment Overview

The management of pediatric EoE focuses on controlling esophageal inflammation, achieving histological remission, improving symptoms and preventing progressive remodeling and strictures. Current strategies include proton pump inhibitors, swallowed topical corticosteroids, empiric or targeted elimination diets and endoscopic dilation for clinically significant narrowing. The 2024 ESPGHAN guideline recommends individualized dietary or pharmacological treatment with endoscopic and histological reassessment. Dupilumab substantially expanded pediatric treatment options: the US FDA expanded its EoE indication in January 2024 to children aged 1 year and older weighing at least 15 kg. Budesonide oral suspension (Eohilia) was approved in February 2024 for adults and pediatric patients aged 11 years and older for a 12-week treatment course. These approvals represent important advances, although long-term disease-modifying treatment, treatment sequencing, access and monitoring remain areas of continuing clinical need.

Key Questions Answered

  • What is the current and projected burden of Pediatric Eosinophilic Esophagitis (EoE) across the 8 major markets?
  • Which countries across the 8 major markets account for the highest Pediatric Eosinophilic Esophagitis (EoE) patient populations and fastest growth rates?
  • What is the diagnosed versus undiagnosed patient population of Pediatric Eosinophilic Esophagitis (EoE) across key countries in the 8 major markets?
  • Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of Pediatric Eosinophilic Esophagitis (EoE) across the 8 major markets?
  • What are the major drivers contributing to the increasing burden of Pediatric Eosinophilic Esophagitis (EoE) across the 8 major markets?
  • How do major comorbidities and risk factors influence Pediatric Eosinophilic Esophagitis (EoE) epidemiology trends across the 8 major markets?
  • What are the regional trends in advanced disease progression, treatment uptake, and patient management of Pediatric Eosinophilic Esophagitis (EoE) across the 8 major markets?
  • Which patient segments represent the highest unmet clinical need in the Pediatric Eosinophilic Esophagitis (EoE) landscape across the 8 major markets?
  • Which therapeutic areas linked to Pediatric Eosinophilic Esophagitis (EoE) are expected to witness the strongest growth opportunities across the 8 major markets?
  • How is the Pediatric Eosinophilic Esophagitis (EoE) epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
  • Which countries across the 8 major markets offer the most attractive market opportunities based on Pediatric Eosinophilic Esophagitis (EoE) epidemiology and healthcare infrastructure?
  • Which epidemiological trends are expected to influence future drug development and market access strategies for Pediatric Eosinophilic Esophagitis (EoE) across the 8 major markets?

Scope of the Pediatric Eosinophilic Esophagitis (EoE) Epidemiology Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Pediatric Eosinophilic Esophagitis (EoE) based on several factors.
  • Pediatric Eosinophilic Esophagitis (EoE) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The Pediatric Eosinophilic Esophagitis (EoE) report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Esophageal Cancer Market

Esophageal Achalasia Epidemiology Forecast

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Report Features

Details

Base Year

2025

Historical Period

2019-2025

Forecast Period

2026-2035

Epidemiology Statistics Provided

  • Diagnosed Prevalent Cases
  • Type-Specific Cases
  • Gender-Specific Cases
  • Age-Specific Cases

Segmentation Provided

  • Epidemiology by Age Group
  • Epidemiology by Gender
  • Epidemiology by Type of Disease
  • Epidemiology by Region

Geographies Covered

  • United States
  • Germany
  • Italy
  • France
  • Spain
  • United Kingdom
  • Japan
  • India

Datasheet

10 % Off

USD

2,699

2,429

Single User License

10 % Off

USD

4,299

3,869

Five User License

15 % Off

USD

5,799

4,949

Corporate License

15 % Off

USD

6,999

5,949

Datasheet

One User

USD 2,699

USD 2,429

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 4,299

USD 3,869

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 5,799

USD 4,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us